Login / Signup

Enhanced efficacy and limited systemic cytokine exposure with membrane-anchored interleukin-12 T-cell therapy in murine tumor models.

Ling ZhangJohn S DaviesCarylinda SernaZhiya YuNicholas P RestifoSteven A RosenbergRichard A MorganChristian S Hinrichs
Published in: Journal for immunotherapy of cancer (2020)
Expression of aIL-12 by tumor-targeting therapeutic T cells demonstrated low systemic exposure and improved efficacy. This treatment strategy may have broad applications to cellular therapy with tumor-infiltrating lymphocytes, chimeric antigen receptor T cells, and TCR T cells.
Keyphrases
  • poor prognosis
  • regulatory t cells
  • peripheral blood
  • cancer therapy
  • immune response
  • combination therapy
  • long non coding rna
  • bone marrow